Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: An international retrospective study

Henrik Hasle, Todd A. Alonzo, Anne Auvrignon, Catherine Behar, Myron Chang, Ursula Creutzig, Alexandra Fischer, Erik Forestier, Alcira Fynn, Oskar A. Haas, Jochen Harbott, Christine J. Harrison, Nyla A. Heerema, Marry M. Van Den Heuvel-Eibrink, Gertjan J.L. Kaspers, Franco Locatelli, Peter Noellke, Sophia Polychronopoulou, Yaddanapudi Ravindranath, Bassem RazzoukDirk Reinhardt, Natalia N. Savva, Batia Stark, Stefan Suciu, Ichiro Tsukimoto, David K. Webb, Dorora Wojcik, William G. Woods, Martin Zimmermann, Charlotte M. Niemeyer, Susana C. Raimondi

Research output: Contribution to journalArticleAcademicpeer-review

129 Citations (Scopus)

Abstract

Monosomy 7 (-7) and deletion 7q [del(7q)] are rare in childhood acute myeloid leukemia (AML). We retrospectively collected data on 258 children with AML or refractory anemia with excess blasts in transformation (RAEB-T) and -7 or del(7q) with or without other cytogenetic aberrations [± other]. Karyotypes included -7 (n = 90), -7 other (n = 82), del(7q) (n = 21), and del(7q) other (n = 65). Complete remission (CR) was achieved in fewer patients with -7 ± other compared with del(7q) ± other (61% versus 89%, P < .001). Overall, the 5-year survival rate was 39% (SE, 3%). Survival was superior in del(7q) ± other compared with -7 ± other (51% versus 30%, P < .01). Cytogenetic aberrations considered favorable in AML [t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q22;q21), t(9;11)(p22;q23)] (n = 24) were strongly associated with del(7q) and a higher 5-year survival rate compared with del(7q) without favorable cytogenetics (75% versus 46%, P = .03). Patients with -7 and inv(3),-5/del(5q), or +21 had a 5-year survival rate of 5%. Stem cell transplantation analyzed as a time-dependent variable had no impact on overall survival. However, patients not achieving CR had a 31% survival rate after stem cell transplantation. Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having a major prognostic impact which should be reflected in future riskgroup stratification.

Original languageEnglish
Pages (from-to)4641-4647
Number of pages7
JournalBlood
Volume109
Issue number11
DOIs
Publication statusPublished - 1 Jun 2007

Cite this